APP gains penicillin approval

Schaumburg-based APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., announced that it has received approval from the U.S. Food and Drug Administration to market penicillin G potassium for Injection, USP, in two dosage strengths. Penicillin G is therapeutically equivalent to the reference drug PfizerPen G, which is marketed by the innovator Pfizer Inc. APP will package Penicillin G in 5 million and 20 million unit single dose vials.